EGFR / BCL-XL

Class

Antibody-drug conjugate: EGFR-targeting antibody conjugated to a BCL-XL inhibitor payload (discontinued 2023)

Pathway

EGFR-directed delivery of a BCL-XL (anti-apoptotic protein) inhibitor payload; BCL-XL inhibition reactivates the apoptotic pathway in tumor cells

EGFR (epidermal growth factor receptor) is a cell-surface receptor found in abundance on many epithelial tumor cells, where it drives signals for growth and survival. In this mechanism, EGFR itself is not the therapeutic target but a docking point: an antibody that recognizes EGFR is chemically linked to a small-molecule payload that inhibits BCL-XL, a protein belonging to the BCL-2 family of anti-apoptotic regulators. Tumor cells often upregulate BCL-XL to suppress apoptosis, the programmed cell death process that would normally eliminate damaged or abnormal cells. Blocking BCL-XL removes this survival brake and can reactivate the apoptotic pathway, prompting tumor cell death. Delivering the BCL-XL inhibitor as an antibody-drug conjugate rather than a freely circulating small molecule addresses a known limitation of this drug class: platelets also depend on BCL-XL to survive, so direct, systemic BCL-XL inhibition tends to lower platelet counts. By attaching the inhibitor to an EGFR-targeting antibody, exposure is intended to concentrate in EGFR-expressing tumor tissue while sparing normal cells that lack high EGFR levels. This general strategy is relevant to solid tumors with high EGFR expression, particularly those that resist chemotherapy or targeted agents by leaning on anti-apoptotic signaling for survival.